Related Experiment Video
Updated: Sep 25, 2026
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule
Bryon D Johnson1, Xiaocai Yan, Dennis W Schauer
1Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226, USA.
Abstract:
A murine model for neuroblastoma, Neuro-2a (N2a), was used to establish a model tumor vaccine. An aggressive subclone of N2a and the less aggressive parental line were transfected with CD80, CD86, or both molecules and stable lines were established. The less aggressive N2a expressing either CD80 or CD86 induced anti-tumor immunity. In contrast, dual expression of CD80 and CD86 was required to initiate a protective anti-tumor immune response against the aggressive subclone. Control of tumor growth was dependent on CD8+ lymphocytes that infiltrated dual-expressing (CD80 and CD86) lesions. These tumor-infiltrating lymphocytes (TIL) exhibited a non-classical mechanism of tumor cell lysis that may require both the up-regulation of cell surface molecules on the tumor and the subsequent lytic activity normally associated with CD8+ TIL. Although Fas was up-regulated by the tumor in the presence of IFN-gamma, N2a and transfected N2a cell lines were not sensitive to Fas-mediated lysis.
Insights
Dual expression of CD80 and CD86 on neuroblastoma cells is necessary for a protective anti-tumor immune response. This immunity relies on CD8+ lymphocytes, suggesting a novel vaccine strategy for aggressive neuroblastoma (N2a) tumors.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Neuroblastoma (N2a) is a pediatric cancer.
- Developing effective tumor vaccines is crucial for cancer treatment.
- Understanding immune evasion mechanisms in aggressive tumors is essential.
Purpose of the Study:
- To establish a murine model for neuroblastoma vaccine development.
- To investigate the role of CD80 and CD86 co-stimulation in anti-tumor immunity.
- To explore novel mechanisms of tumor cell lysis mediated by tumor-infiltrating lymphocytes (TIL).
Main Methods:
- Transfection of Neuro-2a (N2a) cells with CD80, CD86, or both.
- Establishment of stable cell lines with varying co-stimulatory molecule expression.
- Assessment of anti-tumor immunity and tumor growth control in a murine model.
- Analysis of CD8+ lymphocyte infiltration and their lytic mechanisms.
Main Results:
- Single expression of CD80 or CD86 on less aggressive N2a cells induced anti-tumor immunity.
- Dual expression of CD80 and CD86 was required for protective immunity against aggressive N2a subclones.
- Tumor growth control depended on CD8+ TIL infiltrating dual-expressing lesions.
- TIL exhibited a non-classical lysis mechanism, independent of Fas-mediated apoptosis.
Conclusions:
- Co-expression of CD80 and CD86 is critical for potent anti-tumor immunity against aggressive neuroblastoma.
- CD8+ TIL play a key role in controlling tumor growth through a novel cytotoxic mechanism.
- Targeting CD80 and CD86 offers a promising strategy for developing effective neuroblastoma vaccines.
More Related Videos
Related Concept Videos
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Tumor Immunotherapy